ICG plc ICG.L
Composite 52/100; the shares have moved about 30% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 26/100 — a moderate mark against it.
Income ranks 87/100 — a strong point in its favour. Quality ranks 65/100 — a moderate point in its favour. Momentum ranks 57/100 — a slight point in its favour.
Growth ranks 26/100 — a moderate mark against it. Balance-sheet strength ranks 46/100 — a slight mark against it. Valuation ranks 48/100 — a slight mark against it.
What the company does ICG plc is a UK-listed private equity firm focused on direct investments in private debt, venture debt, credit, and equity across mid-market European, US, and Asia-Pacific companies. It also runs fund-of-funds strategies, primarily in secondary private equity transactions, avoiding property, early-stage funds, and start-ups.
Key financials ICG’s profitability remains robust: ROE 18%, ROA 5%, and ROCE 13%. Margins are healthy (gross 100%, operating 46%, net 49%), but revenue and EPS both fell YoY (–21% and –39%). Leverage is moderate (debt/equity 0.47) with a current ratio of 1.59, while dividend yield is 4.5% with a 52% payout ratio.
Stock health Momentum is mixed: +6% over 3m but –11% over 12m, with RSI at 61.40. Quality scores are strong (69/100), but growth (13/100) and momentum (41/100) lag peers. Sideravia ranks ICG in the 54th percentile overall, citing high income (92nd) but weak growth.
Price vs fair value The stock trades at a **discount** of 39.50% to our fair-value estimate and a **discount** of 30.15% to the 12-month analyst target. - Fwd P/E of 10.75 and EV/EBITDA of 9.45 sit below sector medians (Valuation 69.5). - Dividend yield of 4.5% is attractive relative to peers (Income 92.3). - Revenue and EPS declines (-21% and -39%) weigh on growth (Growth 12.5). - Piotroski F-Score of 5/9 and Altman Z of 1.57 signal moderate financial health.
Looking forward Analysts expect a rebound, with a 12-month target implying ~30% upside. Execution on private credit and secondary fund strategies will drive valuation rerating.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.